Perinatal Infections - Global Strategic Business Report

The global market for Perinatal Infections was estimated at US$1.6 Billion in 2024 and is projected to reach US$1.9 Billion by 2030, growing at a CAGR of 3.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Perinatal Infections market.

Global Perinatal Infections Market - Key Trends & Drivers Summarized

Why Are Perinatal Infections a Critical Concern in Neonatal and Maternal Health?

Perinatal infections refer to infections acquired by the fetus or newborn either in utero, during labor and delivery, or shortly after birth. Common pathogens include Group B Streptococcus, Listeria monocytogenes, Escherichia coli, cytomegalovirus, herpes simplex virus, and rubella. These infections can lead to severe complications such as neonatal sepsis, meningitis, pneumonia, stillbirth, or long-term developmental impairments.

Early detection and timely intervention are essential for improving maternal and neonatal outcomes. However, many perinatal infections are asymptomatic or show nonspecific signs, making diagnosis challenging. Global health systems are under growing pressure to enhance prenatal screening, vaccination, and intrapartum infection control, especially in low-resource settings where infection-related mortality remains high.

How Are Screening and Prevention Strategies Evolving Globally?

Prenatal care increasingly includes routine screening for key infectious agents like HIV, hepatitis B, syphilis, and Group B strep. Polymerase chain reaction (PCR) and other molecular techniques are improving diagnostic sensitivity and turnaround time for intrauterine infections. Intrapartum antibiotic prophylaxis (IAP), particularly for Group B strep, has proven effective in reducing early-onset neonatal sepsis.

Vaccination plays a growing role in prevention. Maternal immunization against influenza, pertussis, and hepatitis B helps protect both mother and newborn. Research is advancing in maternal vaccines for respiratory syncytial virus (RSV), Group B strep, and cytomegalovirus. Point-of-care testing tools and digital maternal health platforms are helping expand access to infection management in rural and underserved areas.

Where Is the Focus of Public Health Programs and Clinical Investment Concentrated?

High-income countries have well-established protocols for managing perinatal infections, while middle- and low-income countries are scaling up prenatal testing and maternal immunization programs. Public health agencies, NGOs, and maternal-child health organizations are investing in capacity building for antenatal care, birth preparedness, and infection surveillance.

Hospitals, obstetric clinics, and neonatal intensive care units are integrating rapid diagnostic tools and antimicrobial stewardship strategies. Clinical research is focusing on improved pathogen-specific assays, therapies to manage vertical transmission, and maternal vaccines. The private sector is developing diagnostic kits, multiplex PCR panels, and infection risk scoring algorithms tailored to perinatal care settings.

Growth in the Perinatal Infections market is driven by several factors

Growth in the perinatal infections market is driven by factors such as rising awareness of infection-related neonatal mortality, expansion of prenatal screening programs, and progress in maternal immunization strategies. Global initiatives to reduce neonatal sepsis and prevent stillbirths are intensifying demand for infection control tools and obstetric diagnostics.

Advances in molecular testing technologies, increased deployment of point-of-care diagnostic solutions, and the inclusion of perinatal infection screening in universal antenatal care packages are also supporting market expansion. In addition, regulatory encouragement for maternal vaccines and investment in health infrastructure in low-income countries are contributing to wider adoption of prevention and management solutions.

Scope Of Study:

The report analyzes the Perinatal Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Infection Type (Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection, Other Infections); Treatment (Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment, Other Treatments); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Natural Infection segment, which is expected to reach US$626.4 Million by 2030 with a CAGR of a 4.8%. The Cytomegalovirus Infection segment is also set to grow at 2.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $423.1 Million in 2024, and China, forecasted to grow at an impressive 7.0% CAGR to reach $390.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Perinatal Infections Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Perinatal Infections Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Perinatal Infections Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Becton, Dickinson and Co., bioMérieux, Bio-Rad Laboratories, Cepheid and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 43 companies featured in this Perinatal Infections market report include:

• Abbott Laboratories
• Becton, Dickinson and Co.
• bioMérieux
• Bio-Rad Laboratories
• Cepheid
• Danaher Corporation
• DiaSorin S.p.A.
• EKF Diagnostics
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• Merck & Co., Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• Revvity, Inc. (formerly part of PerkinElmer)
• Siemens Healthineers
• Thermo Fisher Scientific
• Trinity Biotech
• Vircell S.L.
• ZEUS Scientific, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.